TriangleDISEASE & TREATMENT SETTING
Jemperli: recurrent Endometrial cancer with DMMR stated without a specific alteration after prior therapy
Source-derived catalogue. This is not a treatment recommendation or a personalised trial match.
Exact scope
Adult patients with mismatch repair deficient (dMMR) recurrent or advanced endometrial cancer (EC), as determined by an FDA-approved test, that has progressed on or following prior treatment with a platinum-containing regimen.
Broader topic: Endometrial Cancer
- Source population
- Not part of this definition
- Disease extent
- recurrent
- Treatment line
- Not part of this definition
- Stage
- Not part of this definition
- Resectability
- Not part of this definition
Biomarkers, prior therapy and derivation
- molecular
- gene
- DMMR
- alteration
- stated without a specific alteration
- status
- present
- prior therapy
- class
- following prior treatment with a platinum-containing regimen
- status
- required
- derivation status
- source-attested
- derivation note
- Scoped from the FDA approved indication for Jemperli (dostarlimab-gxly) (accelerated-approval table). Only dimensions stated in that wording are part of this definition.
- source wording
- Adult patients with mismatch repair deficient (dMMR) recurrent or advanced endometrial cancer (EC), as determined by an FDA-approved test, that has progressed on or following prior treatment with a platinum-containing regimen.
Study evidence for this setting
No linked study matches these filters. This is a source-coverage gap, not evidence that there are no treatment options.
Source relationships and population-mapping limitations
- bindings
- mappings
Download this complete draft source relationship record →
Preserved source evidence · Not medical advice